Advertisement

Cytomegalovirus Infection Induces Production of Human Interleukin-10 in Macrophages

  • I. Nordøy
  • H. Rollag
  • E. Lien
  • H. Sindre
  • M. Degré
  • P. Aukrust
  • S. S. Frøland
  • F. MüllerEmail author
Article

Abstract

Earlier findings have suggested that the balance between interleukin-10 and tumor necrosis factor α levels in serum may influence the outcome of cytomegalovirus infection in renal transplant recipients. Therefore, the aim of the present study was to investigate whether human cytomegalovirus induces interleukin-10 production in macrophages. Experiments using human cytomegalovirus (strain 2006), ultraviolet-inactivated cytomegalovirus, and mock-infected differentiated THP-1 cells with or without ganciclovir or monoclonal anti-tumor necrosis factor α antibodies were performed. Cytomegalovirus-infected cells produced significantly higher levels of human interleukin-10 mRNA and interleukin-10 than ultraviolet-inactivated cytomegalovirus or mock-infected cells. The addition of ganciclovir had little effect on interleukin-10 production. Anti-tumor necrosis factor α antibodies appeared to reduce the interleukin-10 levels. In conclusion, human cytomegalovirus infection of macrophages induces production of human interleukin-10. This requires viral entry, but not full viral replication.

Keywords

Ganciclovir Renal Transplant Recipient Human Cytomegalovirus Human Monocytic Leukemic Cell Line Human Embryonic Fibroblast Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We thank Bodil Lunden and Solveig Beck for excellent technical assistance. The present experiments comply with current Norwegian laws.

References

  1. 1.
    Ho M (1991) Cytomegalovirus: biology and infection, 2nd edn. Plenum, New YorkGoogle Scholar
  2. 2.
    Dinarello CA (1997) Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 11:91–103PubMedGoogle Scholar
  3. 3.
    Stein J, Volk HD, Liebenthal C, Kruger HD, Prösch S (1993) Tumor necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol 74:2333–2338Google Scholar
  4. 4.
    Fietze E, Prösch S, Reinke P, Stein J, Döcke WD, Staffa G, Löning S, Devaux S, Emmerich F, von Baehr R, Krüger DH, Volk DH (1994) Cytomegalovirus infection in transplant recipients: the role of tumor necrosis factor. Transplantation 58:675–684PubMedGoogle Scholar
  5. 5.
    Hummel M, Zhang Z, Yan S, Deplaen I, Golia P, Varghese T, Thomas G, Abecassis MI (2001) Allogeneic transplantation induced expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J Virol 75:4814–4822PubMedGoogle Scholar
  6. 6.
    Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 19:683–765Google Scholar
  7. 7.
    Redpath S, Ghazal P, Gascoigne NRJ (2001) Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 9:86–92PubMedGoogle Scholar
  8. 8.
    Nordøy I, Müller F, Nordal KP, Rollag H, Lien E, Aukrust P, Frøland SS (2000) The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 181:51–57PubMedGoogle Scholar
  9. 9.
    Sindre H, Rollag H, Degré M, Hestdal K (2000) Human cytomegalovirus induced inhibition of hematopoietic cell line growth is initiated by events taking place before translation of viral gene products. Arch Virol 145:99–111PubMedGoogle Scholar
  10. 10.
    Talbot P, Almeida JD (1977) Human cytomegalovirus: purification of enveloped virions and dense bodies. J Gen Virol 36:345–349Google Scholar
  11. 11.
    Michelson S (1998) Mechanisms of immunosuppression by human cytomegalovirus. In: Scholtz M, Rabenau HF, Doerr HW, Cinatl J Jr (eds) CMV related immunopathology. Monographs in virology, vol. 21. Karger, Basel, pp 12–28Google Scholar
  12. 12.
    Odeberg J, Söderberg-Nauclér C (2001) Reduced expression of HLA class II molecules and interleukin-10 and transforming growth factor β1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures. J Virol 75:5174–5181PubMedGoogle Scholar
  13. 13.
    Geist L, Hinde SL (2001) Susceptibility to cytomegalovirus infection may be dependent on the cytokine response to the virus. J Invest Med 49:434–441Google Scholar
  14. 14.
    Redpath S, Angulo A, Gascoigne NRJ, Ghazal P (1999) Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol 162:6701–6707PubMedGoogle Scholar
  15. 15.
    Plachter B, Sinzger C, Jahn G (1996) Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 46:195–261PubMedGoogle Scholar
  16. 16.
    Van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SHJ (1994) Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 180:1985–1988PubMedGoogle Scholar
  17. 17.
    Kotenki SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S (2000) Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci USA 97:1695–1700PubMedGoogle Scholar
  18. 18.
    Spencer JV, Lockridge KM, Barry PA, Lin G, Tsang M, Penfold MET, Schall TJ (2002) Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76:1285–1292PubMedGoogle Scholar
  19. 19.
    Ritter T, Brandt C, Prösch S, Vergopoulos A, Vogt K, Kolls J, Volk HD (2002) Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promotor activity in human endothelial cells. Cytokine 12:1163–1170CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • I. Nordøy
    • 1
  • H. Rollag
    • 1
  • E. Lien
    • 2
    • 4
  • H. Sindre
    • 1
  • M. Degré
    • 1
  • P. Aukrust
    • 3
  • S. S. Frøland
    • 3
  • F. Müller
    • 1
    Email author
  1. 1.Institute of MicrobiologyRikshospitaletOsloNorway
  2. 2.Department of Cancer Research and Molecular BiologyThe Norwegian University of Science and TechnologyTrondheimNorway
  3. 3.Department of Medicine, Section of Clinical Immunology and Infectious Diseases, Research Institute of Internal MedicineRikshospitaletOsloNorway
  4. 4.Department of MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations